Multiple sclerosis and related disorders · 2025
Assessing the central vein sign in multiple sclerosis using contrast-enhanced isotropic FLAIR* on a 1.5T System: A prospective observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Senturk Yunus Emre, Peker Ahmet, Ozen Atalay Hande, Altintas Ayse, Oner Ali Yusuf
Аннотация
OBJECTIVE: Central vein sign (CVS) in isotropic FLAIR* imaging is a successful marker for multiple sclerosis (MS). Our objective is to explore the prevalence of gadolinium-based contrast agent (GBCA) enhanced FLAIR* in a 1.5 T system for CVS assessment.
MATERIALS AND METHODS: This prospective observational study, conducted from February 2022 to February 2023, involved 41 participants with MS using 1.5T and 28 participants using 3T GBCA-enhanced FLAIR*. First, the eligibility of each demyelinating lesion was determined based on the NAIMS-CVS criteria. Then the CVS-eligible lesions were classified as CVS+ or CVS- by the central rater and co-rater (A.P.). CVS+ prevalence was assessed using the Select-n* and percentage-based methods.
RESULTS: Out of 895 CVS-eligible lesions, 341 (59.7 %) were CVS+ in the 1.5T group, and 226 (69.7 %) were CVS+ in the 3T group. Thirty-eight (93 %) cases in 1.5T and 25 (89 %) cases in 3T were select-3*(+), while 39 (95 %) cases in 1.5T and 27 (96 %) cases in 3T were select-6*(+), (p > 0.05). Inter and intra-rater reliability for the 1.5T system was substantial (ICC1: 0.79 and ICC2: 0.78). GBCA-enhanced FLAIR* revealed a mean CVS+ of 63 % ± 14.8 in the 1.5T and 72 % ± 13.4 in the 3T group on percentage-based analysis (p = 0.015).
CONCLUSION: GBCA-enhanced FLAIR* in 1.5T systems demonstrated favorable performance in CVS evaluation, despite being less effective compared to the CVS outcomes of GBCA-enhanced FLAIR* at 3T magnetic field strength. This initial finding is significant given the widespread global use of 1.5T systems.
MATERIALS AND METHODS: This prospective observational study, conducted from February 2022 to February 2023, involved 41 participants with MS using 1.5T and 28 participants using 3T GBCA-enhanced FLAIR*. First, the eligibility of each demyelinating lesion was determined based on the NAIMS-CVS criteria. Then the CVS-eligible lesions were classified as CVS+ or CVS- by the central rater and co-rater (A.P.). CVS+ prevalence was assessed using the Select-n* and percentage-based methods.
RESULTS: Out of 895 CVS-eligible lesions, 341 (59.7 %) were CVS+ in the 1.5T group, and 226 (69.7 %) were CVS+ in the 3T group. Thirty-eight (93 %) cases in 1.5T and 25 (89 %) cases in 3T were select-3*(+), while 39 (95 %) cases in 1.5T and 27 (96 %) cases in 3T were select-6*(+), (p > 0.05). Inter and intra-rater reliability for the 1.5T system was substantial (ICC1: 0.79 and ICC2: 0.78). GBCA-enhanced FLAIR* revealed a mean CVS+ of 63 % ± 14.8 in the 1.5T and 72 % ± 13.4 in the 3T group on percentage-based analysis (p = 0.015).
CONCLUSION: GBCA-enhanced FLAIR* in 1.5T systems demonstrated favorable performance in CVS evaluation, despite being less effective compared to the CVS outcomes of GBCA-enhanced FLAIR* at 3T magnetic field strength. This initial finding is significant given the widespread global use of 1.5T systems.